Standard MS DMT ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01317004 (ClinicalTrials.gov)	May 2011	15/3/2011	Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Standard MS DMT	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	61	Phase 4	Italy
2	NCT01216072 (ClinicalTrials.gov)	August 2010	7/9/2010	A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)	Relapsing Forms of Multiple Sclerosis	Drug: Fingolimod;Drug: Standard MS DMTs	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	1053	Phase 4	United States;Canada;Puerto Rico